The FDA's Pharmacy Compounding Advisory Committee is reviewing whether BPC 157 presents significant safety risks and whether compounding pharmacies should be permitted to prepare it as a bulk substance
123 Pegvisomant has also been evaluated in a combination therapy with SRL, particularly with respect to normalizing the IGF1 concentration in acromegalic patients who have failed SRL monotherapy
Testing Round 2 Purity Analysis: The company states this screens for contaminants including heavy metals (lead, mercury, arsenic, cadmium), microbial pathogens (bacteria, yeast, mold), and residual solvents from manufacturing processes
Beyond sleep, DSIP is investigated for its effects on stress adaptation, pain modulation, and neuroendocrine regulation, including potential interactions with cortisol, melatonin, and growth hormone pathways